NSE filing, NSE: LALPATHLAB. Summary written from the filing by ALFA Finder's alert engine.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹1,915.00
- Market cap
- ₹32,143 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 59.3×Sector 52.0×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.
Dr. Lal Pathlabs Acquisition Worth ₹30.3 Cr
Dr. Lal PathLabs subscribed to WOS PUPL equity to fund PUPL's buyout of remaining 30% in CentraPath Labs for ₹30.3 Crore. CentraPath becomes a wholly owned subsidiary.
- Value
- ₹30.30 Cr
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs submitted the quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, received from its RTA.
Dr. Lal Pathlabs Legal & Regulatory
Dr. Lal PathLabs disclosed an ITAT tax appeal against a favorable order for Rs.32.66 Crore ESOP expense relief (AY 2022-23). The company expects no material financial impact.
- Value
- ₹32.66 Cr
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs reported PIT disclosures for trades by designated persons and its Employee Welfare Trust, totaling approximately ₹0.83 Crore. These involved ESOP allotments and market sales.
- Value
- ₹0.09 Cr
Dr. Lal Pathlabs Acquisition Worth ₹38 Cr
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
- Value
- ₹38.00 Cr
Other financial results announcements
All →RPG Life Sciences Q2 FY27 Results: Net Profit ₹28.2 Cr, Down 23.6% YoY
RPG Life Sciences Ltd reported revenue from operations of ₹211.6 Cr (+16.5% YoY) and net profit of ₹28.2 Cr (-23.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹28.2 Cr · -23.6% YoY
Alldigi Tech Q2 FY27 Results: Net Profit ₹26.6 Cr, Up 51.1% YoY
Alldigi Tech Ltd reported revenue from operations of ₹153.3 Cr (+4.0% YoY) and net profit of ₹26.6 Cr (+51.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹26.6 Cr · +51.1% YoY
Krishna Defence and Allied Industries Q2 FY27 Results: Net Profit ₹1,532 Cr, Up 71.8% YoY
Krishna Defence and Allied Industries Ltd reported revenue from operations of ₹7,529 Cr (+55.7% YoY) and net profit of ₹1,532 Cr (+71.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,532 Cr · +71.8% YoY
Bandaram Pharma Packtech Q2 FY27 Results: Net Profit ₹0.2 Cr, Up 100.0% YoY
Bandaram Pharma Packtech reported audited standalone and consolidated results for the quarter and half-year ended 30.09.2026. Consolidated revenue from operations for the half-year was Rs 4,540.28 lakhs.
- Key figure
- Net profit ₹0.2 Cr · +100.0% YoY
CARE Ratings Q2 FY27 Results: Net Profit ₹72.4 Cr, Up 26.6% YoY
CARE Ratings Ltd reported revenue from operations of ₹164.1 Cr (+20.3% YoY) and net profit of ₹72.4 Cr (+26.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹72.4 Cr · +26.6% YoY
Seshaasai Technologies Q2 FY27 Results: Net Profit ₹69.7 Cr, Up 21.0% YoY
Seshaasai Technologies Ltd reported revenue from operations of ₹405.3 Cr (+15.0% YoY) and net profit of ₹69.7 Cr (+21.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹69.7 Cr · +21.0% YoY